Search results for "N.M.B."

showing 10 items of 684 documents

Effects of preoperative aquatic resistance training on knee pain, mobility limitation and muscle impairments in people with late-stage knee osteoarth…

2015

medicine.medical_specialtyKnee painMobility Limitationbusiness.industrymedicineLate stagePhysical therapyResistance trainingPhysical Therapy Sports Therapy and RehabilitationOsteoarthritismedicine.symptombusinessmedicine.diseasePhysiotherapy
researchProduct

Duodenal and rectal varices as a source of severe upper and lower gastrointestinal bleeding

2009

medicine.medical_specialtyLower gastrointestinal bleedingDuodenumbusiness.industryGeneral surgeryRectumGastroenterologyMiddle Agedmedicine.diseaseGastroenterologyEndoscopy GastrointestinalVaricose VeinsRectal varicesInternal medicinemedicineHumansGastrointestinal HemorrhagebusinessLigationEndoscopy
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Feasibility of future epidemiological studies on possible health effects of mobile phone base stations.

2006

The increasing deployment of mobile communication base stations led to an increasing demand for epidemiological studies on possible health effects of radio frequency emissions. The methodological challenges of such studies have been critically evaluated by a panel of scientists in the fields of radiofrequency engineering/dosimetry and epidemiology. Strengths and weaknesses of previous studies have been identified. Dosimetric concepts and crucial aspects in exposure assessment were evaluated in terms of epidemiological studies on different types of outcomes. We conclude that in principle base station epidemiological studies are feasible. However, the exposure contributions from all relevant …

medicine.medical_specialtyPhysiologybusiness.industryRadio WavesPublic healthBiophysicsGeneral MedicineEnvironmental exposureEnvironmental ExposureSensitivity and SpecificityBase stationMobile phoneEnvironmental healthEpidemiologic Research DesignEpidemiologyMedicineHumansRadiology Nuclear Medicine and imagingMobile telephonyPublic HealthbusinessMicrowavesStrengths and weaknessesCell PhoneExposure assessmentBioelectromagnetics
researchProduct

Power of lower extremities and age were the main determinants on the agility test for adults in a cohort of men aged 66–91 years

2019

Study Design: Cross-sectional study. Objective: To evaluate the relationship between agility and personal factors, muscle strength and power, mobility, self-reported balance and physical activity among older men. Methods: Agility was measured by using the Agility Test for Adults (ATA). We studied 100 Finnish male former elite athletes (endurance n = 50; power n = 50) and 50 matched controls aged 66 to 91 years (mean age 75.5 years). The associations between agility and other variables were similar between three groups; thus, multiple linear regression analyses were done by using the pooled data of the participants. Results: On the basis of multiple linear regression analyses, combination of…

medicine.medical_specialtyPopulationPhysical Therapy Sports Therapy and RehabilitationPower (social and political)MUSCLE STRENGTH03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationphysical functioningMedicineOF-DIRECTION SPEED030212 general & internal medicine315 Sport and fitness sciencesmotoriset taidoteducationMETAANALYSISPOPULATIONMotor skillBalance (ability)countermovement jumpeducation.field_of_studymotor skillsbusiness.industryTO-STAND TEST030229 sport sciencesPERFORMANCETest (assessment)AgeingPHYSICAL-ACTIVITYikääntyminenMOBILITYageingAgeingBALANCECohortMuscle strengthmiehetTEST-RETEST RELIABILITYliikkuminenbusinessfyysinen aktiivisuusfeasibilitylihasvoimaEuropean Journal of Physiotherapy
researchProduct

2020

Abstract Background Stroke is a major cause of disability and stroke incidence increases with age. Stroke frequently results in permanent limitations of mobility, and, consequently, the need for the help of others in activities of daily living. In order to optimize rehabilitative efforts and their functional outcomes, detailed knowledge of the functional recovery process, regarding mobility, is needed. Objectives of the MOBITEC-Stroke study are: 1.) To characterize mobility, including lower extremity physical function (LEPF) and life space (the geospatial extent of all of a person’s movements), and changes in mobility within the first year after stroke. 2.) To identify and characterize subg…

medicine.medical_specialtyRehabilitationActivities of daily livingbusiness.industrymedicine.medical_treatmentSample (statistics)General Medicinemedicine.diseasePreferred walking speed03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Physical medicine and rehabilitationMobility LimitationSample size determinationMedicine030212 general & internal medicineNeurology (clinical)businessStroke030217 neurology & neurosurgeryBMC Neurology
researchProduct

In vitro comparison of platinum-iridium and gold tip electrodes: lesion depth in 4 mm, 8 mm, and irrigated-tip radiofrequency ablation catheters

2009

Aims We compared a newly developed irrigated gold tip electrode ablation catheter and a gold tip 4 and 8 mm catheter with the corresponding platinum–iridium (Pt) tip catheters in an in vitro setting. Methods and results In a flow chamber simulating physiological flow conditions, radiofrequency catheter ablation was performed on tissue samples of porcine endomyocardium and liver. Lesion depth, energy and temperature delivery, and popping frequency were determined. Two hundred and fifty-three ablations were conducted. Four and eight millimetre, gold tip electrode catheters produced significantly deeper lesions compared with the Pt tip electrode (liver 4 mm: 4.67 ± 1.7 vs. 2.9 ± 1.0 mm, P < 0.…

medicine.medical_specialtySwineRadiofrequency ablationmedicine.medical_treatmentchemistry.chemical_elementIn Vitro TechniquesIridiumlaw.inventionlawPhysiology (medical)medicineAnimalsIridiumCardiac Surgical ProceduresElectrodesPlatinumbusiness.industryLesion depthAblationSurgeryCatheterLiverchemistryRadiofrequency catheter ablationModels AnimalElectrodeCatheter AblationGoldCardiology and Cardiovascular MedicinePlatinumbusinessNuclear medicineEuropace
researchProduct

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

2020

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

medicine.medical_specialtyTildrakizumabBiolgical therapy; COVID-19; PsoriasisSettore MED/35PsoriasisChronic Disease; Emergencies; Humans; Italy; Psoriasis; Biological Therapy; COVID-19UstekinumabmedicineAdalimumabHumansPsoriasisbiologicsIntensive care medicineLetter to the Editorpsoriasipsoriasis; biologics; covid-19; pandemicEmergenciePsoriasiRisankizumabbusiness.industrySARS-CoV-2pandemicBiolgical therapyCOVID-19medicine.diseasedermatologyBiological TherapyIxekizumabGuselkumabInfectious Diseasescovid-19ItalyChronic DiseaseSecukinumabEmergenciesbusinessSettore MED/35 - MALATTIE CUTANEE E VENEREEbiologicCOVID-19 psoriasis biological therapiesmedicine.drugHuman
researchProduct

What Is the Impact of Innovative Electronic Health Interventions in Improving Treatment Adherence in Asthma? The Pediatric Perspective

2019

Suboptimal adherence to treatment is a significant issue in the management of pediatric asthma and is a major cause of uncontrolled disease, life-threatening attacks, and increased utilization of healthcare resources. Electronic health (e-Health) solutions have the potential to positively impact asthma self-management in children and adolescents and their families, thereby improving treatment adherence and asthma outcomes. However, there is a lack of sufficient data to support widespread adoption of e-Health tools in pediatric asthma practice. A critical evaluation of the impact of these new interventions on treatment adherence in childhood asthma must consider unmet needs, heterogeneity of…

medicine.medical_specialtyTreatment adherencePsychological interventionMobile applicationDiseaseElectronic monitoring devicesPediatrics03 medical and health sciences0302 clinical medicineMobile applicationsInventionsAsthma controlHealth caremedicineHumansImmunology and Allergy030212 general & internal medicineChildIntensive care medicinemHealthChildrenAsthmaChildhood asthmabusiness.industryPerspective (graphical)medicine.diseaseQuality ImprovementTelemedicineAsthmaTreatment Adherence and ComplianceItaly030228 respiratory systemElectronic monitoring deviceAdherencee-Healthbusiness
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct